S-Adenosyl-L-Methionine (SAMe) Dosing for Liver Support

Introduction to SAMe Therapy

• The European Association for the Study of the Liver (EASL) explicitly states that no specific pharmacological therapy for alcoholic cirrhosis, including SAMe, has demonstrated unequivocal efficacy 1, 2, 3
• The American Association for the Study of Liver Diseases noted that while one trial showed statistically significant improvement in survival for Child-Pugh A and B cirrhosis patients, the overall Cochrane analysis did not demonstrate benefit 4

Clinical Decision Making

• For patients with alcoholic liver disease, prioritize alcohol abstinence as the major therapeutic goal (strongest evidence for mortality reduction) 1, 2, 3
• Consider SAMe 1200 mg daily only as adjunctive therapy with clear patient counseling that mortality benefit is unproven 1

Treatment Approach

• The standard dose of S-adenosyl-L-methionine (SAMe) for liver support is 1200 mg orally per day, typically divided into doses 1, 2, 3
• Treatment duration in clinical trials has ranged from 6 months to 2 years 4

Important Considerations

• Do not use SAMe as a substitute for alcohol abstinence or standard cirrhosis management 1, 2, 3
• Do not prescribe SAMe expecting mortality reduction or prevention of decompensation based on current evidence 4